Deferring percutaneous coronary intervention (PCI) in transcatheter aortic valve implantation (TAVI) significantly reduces bleeding in patients with coronary artery disease (CAD) and is noninferior to the standard of PCI before TAVI, data from the PRO-TAVI trial show.